Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in height · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in longitudinal growth: change in height SDS compared with placebo or no intervention (low certainty).
1 finding from 1 review
Measures of mineral metabolism: change in serum phosphate mmol/L · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of mineral metabolism: change in serum phosphate mmol/L compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Alkaline phosphatase · children with X‐linked hypophosphataemia
1 finding from 1 review
Measures of renal function: change in TmP/GFR · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of renal function: change in TmP/GFR compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Body proportions: sitting height SDS · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse effects · children with X‐linked hypophosphataemia
1 finding from 1 review
Outcome category – outcome(s)* · migrants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health literacy – (1) Appraising health information · migrants
1 finding from 1 review
Quality of life ‐ not measured · migrants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health outcome – not measured · migrants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health behaviour – PSA testing · migrants
Culturally and literacy adapted telephone education showed no clear difference in health behaviour – PSA testing compared with unrelated health literacy intervention (moderate certainty).
1 finding from 1 review
Self‐efficacy ‐ not measured · migrants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health service use – not measured · migrants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety (adverse effect, post‐intervention) · migrants
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with 2 times/week (low certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: adverse events compared with 2 times/week (low certainty).
1 finding from 1 review